Fudan Zhangjiang recently disclosed its 2025 annual report, revealing annual revenue of 686 million yuan and a net loss of 157 million yuan. Despite short-term performance pressure, the company has not slowed its innovation pace. Annual R&D expenditure reached 358 million yuan, a 14% year-on-year increase, with R&D intensity rising to 52% of revenue, up 8 percentage points from the previous year. This high level of R&D investment solidifies its core competitiveness and demonstrates strong confidence in its medium to long-term development.

Beneath the surface figures, is this a strategic choice or a fundamental slowdown? While annual net profit attributable to shareholders turned negative, a deeper analysis shows the profit fluctuation is not due to weakened core business competitiveness. Instead, it results from a combination of short-term external shocks and internal strategic adjustments, representing a transitional phase rather than a fundamental decline. The company's former key product, Libao, was not selected in the tenth national drug procurement round. In response to procurement rules and market competition, Fudan Zhangjiang adjusted its sales strategy for this product, leading to approximately 100 million yuan less profit contribution compared to the previous year, constituting the main external factor for the performance decline. Simultaneously, the company maintained its innovation-driven strategy, increasing R&D investment by over 44 million yuan, further squeezing short-term profitability. This trajectory is common among innovative Chinese pharmaceutical companies – novel drug development is characterized by long cycles, high investment, and significant risk. Short-term performance pressures are an inevitable phase for companies committed to innovation and future growth, representing necessary accumulation for achieving long-term value breakthroughs.

Through technological integration, the company is building new barriers combining photodynamic therapy and ADC expertise. As a global leader in photodynamic drugs, Fudan Zhangjiang's R&D spending remains precisely focused on two core areas: photodynamic drugs and antibody-drug conjugates, while proactively exploring integration of these technologies. This differentiated innovation helps avoid industry homogenization and continuously strengthens its leading position. According to the report, in photodynamics, the company is rapidly expanding from traditional dermatology treatments into intraoperative visual diagnosis for tumors, achieving key breakthroughs in integrated diagnosis and treatment, thereby broadening the clinical applications of photodynamic technology. Several pipelines reached milestones: the ALA project for visual guidance during glioma surgery has formally submitted a registration application, currently under regulatory review; the FZ-P001 sodium project for visualizing malignant lesions during ovarian cancer surgery received Phase I clinical approval, while its application for lung cancer surgery simultaneously obtained Phase II clinical approval. Fudan Zhangjiang continues to maximize the "one drug, multiple indications" advantage of photodynamic drugs, building a unique product portfolio distinct from traditional treatments that covers various diseases, reinforcing its global leadership in photodynamics.

In antibody-drug conjugates, leveraging its proprietary differentiated linker-drug platform, Fudan Zhangjiang is targeting areas with unmet clinical needs, avoiding homogeneous competition. The Trop2-SN38 project for treating triple-negative breast cancer completed Phase III patient enrollment ahead of schedule, with over 350 participants enrolled. Data analysis is actively progressing, with expectations to soon submit a registration application, making this the company's ADC candidate closest to commercialization. Three other ADC projects based on the BB05 innovative platform are steadily advancing through Phase I/II trials. Among them, the FDA022 project targeting HER2-low breast cancer has completed Phase II enrollment and an end-of-phase II meeting with regulators, indicating a controlled pipeline progression rhythm. Furthermore, the wholly-owned subsidiary Taizhou Fudan Zhangjiang has completed commercial production capacity layout for ADC products ahead of schedule, providing solid support for future pipeline launches.

Additionally, the annual report disclosed前瞻性 exploration in technology integration – based on deep expertise in both photodynamic and ADC technologies, the company is pioneering the new field of antibody-coupled photosensitizers, aiming to lead next-generation targeted therapy technologies. This approach, representing a significant direction for integrating antibody conjugation with photodynamic technology, aims to directly kill tumor cells via targeted photodynamics while rapidly inducing immunogenic cell death, thereby activating adaptive immune responses and significantly improving patient response rates to immunotherapy. Its core advantage lies in achieving "dual targeting" through antibody-mediated "precision navigation" at the molecular level and light-based "localized activation" at the physical level. This enables localized immune modulation within lesions, significantly widening the therapeutic window and reducing systemic toxicity, offering substantial clinical value. This strategic move not only expands Fudan Zhangjiang's technological boundaries but also creates synergy between its two core technology platforms,前瞻性 establishing new platforms, projects, and treatment regimens to inject strong momentum into long-term development.

For Fudan Zhangjiang, short-term performance fluctuations are a transitional cost of adhering to an innovation-focused strategy, not an indication of weakening growth momentum. Moving forward, the company should maintain its focus, deepen innovation efforts, accelerate the industrialization of core pipelines, and gradually unlock long-term value by leveraging its dual strengths in photodynamics and ADCs, its前瞻性 technology integration布局, and solid industrial capabilities, living up to market and investor expectations.